TICKERNERD
Menu
ATRCATRCHealthcare · Medical Instruments & Supplies

ATRC Stock Forecast: AtriCure, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$44
+1.86% on the day

The 10 Wall Street analysts covering AtriCure, Inc. hold a median 12-month price target of $50 — +12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.3B
Ticker Nerd rank
94 / 100
Median analyst target
$50
Analysts covering
10
Total return, dividends reinvested
1W
+7.0%
1M
+29.1%
YTD
+12.0%
1Y
+25.1%
From 52W high
0.0%
From 52W low
+71.3%
$26
$44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATRC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AtriCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Growth
84
Value
75
Accruals
75
Revisions
72
Momentum
67
Volatility
65
Issuance
63
Size
35

Quality (91): The business earns solid, repeatable profits on what it owns.

Issuance (63): The company has been issuing shares or taking on financing, diluting existing holders.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATRC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATRC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ATRCHigh $55Median $50Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $36Median $50High $55

The green dot is the last close — the median target sits +12.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 July 2026UBSMaintainsBuy$55 → $50
6 May 2026Canaccord GenuityMaintainsBuy$53 → $55
6 May 2026Canaccord GenuityMaintainsBuy—
18 Feb 2026BTIGReiteratesBuy—
18 Feb 2026Canaccord GenuityMaintainsBuy—
18 Feb 2026CitizensMaintainsMarket Outperform—
18 Feb 2026OppenheimerDowngradePerform—
18 Feb 2026UBSMaintainsBuy—
12 Feb 2026NeedhamReiteratesBuy—
16 Dec 2025JP MorganMaintainsOverweight—
30 Oct 2025Canaccord GenuityMaintainsBuy—
30 July 2025NeedhamMaintainsBuy—
30 Apr 2025BTIGMaintainsBuy—
30 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
30 Apr 2025NeedhamMaintainsBuy—
30 Apr 2025UBSMaintainsBuy—
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
28 Mar 2025Canaccord GenuityMaintainsBuy—
27 Mar 2025BTIGMaintainsBuy—
27 Mar 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATRC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ATRC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+103.2%
Analysts raising
5
Analysts cutting
0
Fundamentals

AtriCure, Inc. (ATRC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
211.0×

Cheaper than 3% of US stocks

Price / sales
4.0×

Cheaper than 33% of US stocks

Price / book
4.4×

Cheaper than 25% of US stocks

EV / EBITDA
62.8×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
12.8%

Higher than 59% of US stocks

Earnings growth (YoY)
12.8%

Higher than 51% of US stocks

Gross margin
77.2%

Higher than 89% of US stocks

Operating margin
6.3%

Higher than 57% of US stocks

Net margin
1.9%

Higher than 51% of US stocks

Returns & dividend
Return on equity
2.2%

Higher than 48% of US stocks

Return on assets
1.3%

Higher than 52% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATRC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ATRCAtriCure, Inc.$2.3B
94
XRAYDentsply Sirona, Inc.$2.3B
92
LMATLeMaitre Vascular, Inc.$1.9B
74
BLFSBioLife Solutions, Inc.$1.7B
90
KMTSKestra Medical Technologies Ltd.$1.6B
23
PLSEPulse Biosciences, Inc.$3.1B
41
AZTAAzenta, Inc.$1.6B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AtriCure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATRC news & analysis

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

MarketBeat · 12 Aug 2026positive

AtriCure reported continued growth across its atrial fibrillation, left atrial appendage management, and postsurgical pain-management businesses, citing new product adoption, expanding procedure volumes, and progress in clinical trials.

Why it matters — ATRC watchers would care because the company is signaling broadening momentum across multiple business lines and advancing clinical programs.

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The Motley Fool · 7 Aug 2026neutral

Two AtriCure directors reduced their shareholdings following a strong quarter. One transaction involved 3,500 shares sold at $38.42 per share, totaling $134,470 and reducing that director's total equity holdings by 20%, per the Form 4.

Why it matters — ATRC watchers would care because insider selling can signal director confidence and is relevant when assessing insider activity after a strong quarterly performance.

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

The Motley Fool · 7 Aug 2026neutral

AtriCure director Karen Prange sold 3,564 shares on August 5, for a total transaction value of approximately $138,283. The sale reduced her total direct equity holdings in the company by 14%.

Why it matters — An AtriCure director's significant insider sale is noteworthy for shareholders as insider activity can offer insight into management sentiment.

AtriCure to Participate at Upcoming Investor Conferences

Business Wire · 27 July 2026neutral

AtriCure announced that its management will participate in two upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics Conference on August 10, 2026.

Why it matters — Investor conference participation gives management an opportunity to present the company's strategy and updates to the investment community.

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

Seeking Alpha · 24 July 2026neutral

A transcript of AtriCure's Q2 2026 earnings call was published on Seeking Alpha.

Why it matters — ATRC watchers would review this transcript for management's commentary on quarterly financial performance and business updates.

FAQ

Frequently asked questions about ATRC stock

What is the ATRC stock price forecast for 2026-2027?

The 10 Wall Street analysts covering AtriCure, Inc. have a median 12-month price target of $50, with estimates ranging from $36 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATRC stock a buy right now?

Of the 10 analysts covering AtriCure, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AtriCure, Inc. 94 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATRC?

As at 13 Aug 2026, AtriCure, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will ATRC stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +12.9% from the last close, and Ticker Nerd's factor model ranks AtriCure, Inc. 94 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATRC stock forecast for 2030?

No analyst covering AtriCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATRC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $55 over the next 12 months.

How has ATRC stock performed over the past year?

AtriCure, Inc. returned +25.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AtriCure, Inc. do?

AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management.

What is the latest news on ATRC?

The most recent item we track (MarketBeat, 12 Aug 2026): "AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth". AtriCure reported continued growth across its atrial fibrillation, left atrial appendage management, and postsurgical pain-management businesses, citing new product adoption, expanding procedure volumes, and progress in clinical trials.

Company

About AtriCure, Inc.

AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company develops and provides advanced medical technologies used by electrophysiologists, cardiothoracic surgeons, and thoracic surgeons worldwide to address complex Afib cases and related conditions. Key products include the Isolator Synergy Ablation System, the first medical device approved by the FDA for treating persistent Afib, featuring single-use disposable radiofrequency clamps, multifunctional pens, and linear ablation devices for open and minimally invasive procedures. The AtriClip Left Atrial Appendage Exclusion System offers solutions for LAA management during surgical interventions. Additionally, the Hybrid AF Therapy provides a minimally invasive option for long-standing persistent Afib patients, while the cryoICE cryoSPHERE probes enable temporary ablation of peripheral nerves to alleviate pain in cardiac and thoracic surgeries. AtriCure's EPi-Sense Guided Coagulation System with VisiTrax Technology supports minimally invasive ablation. Headquartered near Cincinnati, Ohio, the company focuses on delivering best-in-class solutions that enhance patient outcomes in cardiothoracic procedures.

CEO Mr. Michael H. Carrel · 1,350 employees · United States · https://www.atricure.com